Use of Nasal Pressure to Assess Inspiratory Effort Under Different Oxygen Treatments

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJian-Xin Zhou

About this trial

The aim of this study was to investigate the effects of different oxygen therapy modalities (including nasal cannula oxygen, mask oxygen and high-flow nasal cannula oxygen) on the correlation between Nasal Pressure and Esophageal Pressure by means of a prospective physiological study, to assess the dynamic changes of nasal pressure and esophageal pressure and their underlying mechanisms under different conditions of oxygen therapy, to analyse the effects of oxygen therapy parameters on the relationship between the two, and to explore the feasibility of nasal pressure as a non-invasive monitoring indicator, in order to replaceor supplement esophageal manometry in clinical practice, especially in patients with respiratory distress and instability.Meanwhile, this study will also evaluate the effects of different oxygen therapy modalities on patients' respiratory mechanics and comfort, provide a scientific basis for the clinical selection of individualised oxygen therapy regimens, and ultimately provide new physiological evidence for the management of oxygen therapy in patients with acute respiratory failure in the intensive care unit (ICU) and outside the ICU, promote the development of non-invasive monitoring technology, and improve the clinical prognosis and therapeutic experience of patients.

Eligibility criteria

Qualifiers

No mechanical ventilation required,Able to tolerate oxygen therapy via nasal cannula, standard face mask, or nasal high-flow oxygen therapy;

Respiratory stability:Capable of spontaneous breathing with effective cough for secretion clearance.Oxygen saturation (SpO₂) > 90% or PaO₂/FiO₂ ≥ 150 mmHg when receiving nasal cannula oxygen at 3 L/min;

Hemodynamic stability:Heart rate (HR) ≤ 120 bpm;Systolic blood pressure (SBP) 90-150 mmHg;No vasoactive medications OR norepinephrine dosage < 0.1-0.2 μg/kg·min (or equivalent doses of other vasoactive agents);

Metabolic stability;

Disqualifiers

Age < 18 years;

Pregnancy;

Hemodynamic instability:Mean arterial pressure (MAP) < 60 mmHg.Heart rate (HR) > 120 bpm or < 60 bpm;

Respiratory instability:Respiratory rate (RR) > 35 bpm.Oxygen saturation (SpO₂) < 90%;

Trial design

Treatments tested in this trial

  • HFNC:50L/min
  • HFNC:flow=40L/min
  • HFNC:flow=30L/min
  • Face mask oxygen:8L/min
  • Face mask oxygen:5L/min
  • Nasal cannula oxygen:5L/min
  • Nasal cannula oxygen:3L/min

Treatment groups

26 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Sponsors and collaborators

Jian-Xin Zhou

Lead sponsor

Capital Medical University

Sponsor institution